Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• Analysts give Stoke Therapeutics an average rating of “Moderate Buy” from 12 brokerages (9 buys, 2 holds, 1 strong buy) with a 12‑month consensus target of about $41.83.
• The company saw notable insider selling
• Stoke is a clinical‑stage biotech (market cap ~$2.12B) developing antisense therapies, led by STK‑001 for Dravet syndrome; it reported a Q EPS of ($0.97) on $1.4M revenue and has negative profitability metrics.

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) has earned an average recommendation of "Moderate Buy" from the twelve brokerages that are presently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation, nine have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $41.8333.

Several analysts recently issued reports on the company. Weiss Ratings restated a "hold (c)" rating on shares of Stoke Therapeutics in a research note on Friday, April 10th. Wolfe Research initiated coverage on Stoke Therapeutics in a research report on Monday, February 23rd. They set an "outperform" rating and a $40.00 target price for the company. BTIG Research reiterated a "buy" rating and set a $39.00 target price on shares of Stoke Therapeutics in a research report on Thursday, March 19th. Chardan Capital reiterated a "buy" rating and set a $35.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, March 18th. Finally, Loop Capital set a $35.00 target price on Stoke Therapeutics in a research report on Monday, January 5th.

Insider Activity

In other news, General Counsel Jonathan Allan sold 4,628 shares of the company's stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $31.34, for a total transaction of $145,041.52. Following the completion of the sale, the general counsel directly owned 28,836 shares in the company, valued at approximately $903,720.24. This represents a 13.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Adrian R. Krainer sold 33,243 shares of the company's stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $39.74, for a total value of $1,321,076.82. Following the sale, the director owned 283,302 shares of the company's stock, valued at approximately $11,258,421.48. The trade was a 10.50% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 69,699 shares of company stock worth $2,526,714. 9.50% of the stock is owned by insiders.

Institutional Trading of Stoke Therapeutics

A number of institutional investors have recently modified their holdings of STOK. Kestra Advisory Services LLC bought a new stake in shares of Stoke Therapeutics during the 4th quarter valued at $26,000. Harbour Investments Inc. raised its holdings in shares of Stoke Therapeutics by 312.9% during the 4th quarter. Harbour Investments Inc. now owns 1,185 shares of the company's stock worth $38,000 after buying an additional 898 shares in the last quarter. Generali Investments Management Co LLC acquired a new position in shares of Stoke Therapeutics during the 3rd quarter worth $41,000. BNP Paribas Financial Markets raised its holdings in shares of Stoke Therapeutics by 66.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company's stock worth $48,000 after buying an additional 1,668 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Stoke Therapeutics by 461.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company's stock worth $50,000 after buying an additional 3,591 shares in the last quarter.

Stoke Therapeutics Price Performance

STOK opened at $34.03 on Friday. The business has a fifty day simple moving average of $34.41 and a 200 day simple moving average of $32.00. The company has a market capitalization of $2.12 billion, a PE ratio of -283.56 and a beta of 1.22. Stoke Therapeutics has a 1 year low of $8.30 and a 1 year high of $40.22.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last released its quarterly earnings results on Monday, March 16th. The company reported ($0.97) earnings per share (EPS) for the quarter. The firm had revenue of $1.40 million during the quarter. Stoke Therapeutics had a negative net margin of 3.73% and a negative return on equity of 2.05%. Equities analysts anticipate that Stoke Therapeutics will post -3.41 earnings per share for the current fiscal year.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company's lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.